Samsung Biologics is again in the spotlight over its 2016 initial public offering as prosecutors raided the office of the Korea Exchange.
Prosecutors suspect the stock market operator eased regulations to allow the CMO to list on the country's top-tier stock market. During the raid, investigators collected documents and hard drives, looking for information related to the IPO.
Last year, financial regulators accused Samsung Biologics of committing a $4 billion accounting fraud in 2015, inflating its value tied to its Biogen-partnered affiliate Samsung Bioepis.
Read the Asian Review coverage